Chao Lu

Taiwan Semiconductor Manufacturing Company (China) — China

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index798citations54works2.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

MicroRNA in disease regulation(5), Circular RNAs in diseases(5), Bladder and Urothelial Cancer Treatments(4), Cancer-related molecular mechanisms research(4), Myasthenia Gravis and Thymoma(4)

Publications54 total

Evaluating the impact of FSDOI physical design strategies on automotive-grade semiconductor chip reliability and performance
Journal of Computational Methods in Sciences and Engineering·2025
Nicotinamide mononucleotide protects septic hearts in mice via preventing cyclophilin F modification and lysosomal dysfunction
Acta Pharmacologica Sinica·2024· 11 cited
The application of extraocular muscle maximum standardized uptake value of 99mTc-diethylenetriamine pentaacetic acid orbital single photon emission computed tomography/computed tomography in the assessment of Graves’ orbitopathy
Nuclear Medicine Communications·2024
Correction to: Stimulating thyroglobulin to TSH ratio predict long-term efficacy of 131I therapy in patients with differentiated thyroid cancer after total thyroidectomy: a retrospective study
Endocrine·2024Open Access
313.6: Establishment of a genetic signature of ischemia reperfusion injury in a porcine pancreas transplantation model
Transplantation·2023
Nuclear Protein 1 Expression Is Associated with PPARG in Bladder Transitional Cell Carcinoma
PPAR Research·2023· 2 citedOpen Access
Associations of Genetic Polymorphisms of mTOR rs2295080 T/G and rs1883965 G/A with Susceptibility of Urinary System Cancers
Disease Markers·2022· 7 citedOpen Access
A Five Collagen-Related Gene Signature to Estimate the Prognosis and Immune Microenvironment in Clear Cell Renal Cell Cancer
Vaccines·2021· 4 citedOpen Access
A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects
Expert Opinion on Biological Therapy·2021· 1 cited
A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Clinical Trial to Assess Safety, Tolerability, and Pharmacokinetics of LY-CovMab, a Potent Human Neutralizing Antibody Against SARS-CoV-2
Infectious Diseases and Therapy·2021· 4 citedOpen Access
Comparing Prognosis Associated with Partial Cystectomy and Trimodal Therapy for Muscle-Invasive Bladder Cancer Patients
Urologia Internationalis·2021· 3 cited
Comparison of the effects of retroperitoneoscopic ureterolithotomy and ureteroscopic lithotripsy in the treatment of upper ureteral calculi
Medicine·2021· 4 citedOpen Access
Modified poloxamer 407 and hyaluronic acid thermosensitive hydrogel-encapsulated keratinocyte growth factor 2 improves knee osteoarthritis in rats
Materials & Design·2021· 28 citedOpen Access
Exosome-Derived Long Non-Coding RNAs as Non-Invasive Biomarkers of Bladder Cancer
Frontiers in Oncology·2021· 11 citedOpen Access
Exploration of the core genes in ulcerative interstitial cystitis/bladder pain syndrome
International braz j urol·2021· 6 citedOpen Access
A Five Collagen-related Gene Signature to Estimate the Prognosis and Immune Microenvironment in Clear Cell Renal Cell Cancer
Research Square (Research Square)·2021· 2 citedOpen Access
Clinical effect of Brisson operation modified by Y-shaped incision for treatment of concealed penis in adolescents
Journal of International Medical Research·2021· 4 citedOpen Access
Imbalance of Th17 and Tregs in thymoma may be a pathological mechanism of myasthenia gravis
Molecular Immunology·2021· 27 cited
Prediction of bladder cancer outcome by identifying and validating a mutation-derived genomic instability-associated long noncoding RNA (lncRNA) signature
Bioengineered·2021· 23 citedOpen Access
Toll-like receptor 2 (TLR2) is a candidate prognostic factor in testicular germ cell tumors as well as an indicator of immune function in the tumor microenvironment
Bioengineered·2021· 8 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Sheng‐Hua Wu(10), Lifeng Zhang(9), Shenglin Gao(7), Li Zuo(7), Ji‐Qing Chen(7), Xirong Guo(7), Ronghua Chen(7), Guoping Zhou(6), Songming Huang(6), Ziyi Zhang(5), Wei Ren(5), Quanxin Su(5), Pan Xiao-qin(4), Peng Zhang(3), Guo‐Ping Zhou(3), Li Zuo(3), Xiaokai Shi(3), Xia Chi(3), Mei Guo(3), Fei Li(3)